Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.
J Thromb Haemost. 2016 Aug;14(8):1629-38. doi: 10.1111/jth.13381. Epub 2016 Jul 27.
Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M, Semeraro N.
Thromb Res. 2012 Mar;129(3):314-9. doi: 10.1016/j.thromres.2011.10.031. Epub 2011 Nov 21.
Thrombin-activatable fibrinolysis inhibitor.
Marx PF.
Curr Med Chem. 2004 Sep;11(17):2335-48. doi: 10.2174/0929867043364586.
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
Boffa MB, Koschinsky ML.
Clin Biochem. 2007 Apr;40(7):431-42. doi: 10.1016/j.clinbiochem.2006.10.020. Epub 2006 Nov 21.
Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
Zhou X, Declerck PJ.
J Thromb Haemost. 2015 Jun;13(6):1084-9. doi: 10.1111/jth.12894. Epub 2015 Apr 6.
Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M, Osman N, Hefnawy S, El Hawy MA.
Pediatr Hematol Oncol. 2022 May;39(4):318-328. doi: 10.1080/08880018.2021.1993394. Epub 2021 Oct 20.
Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
Semeraro F, Ammollo CT, Gils A, Declerck PJ, Colucci M.
J Thromb Haemost. 2013 Dec;11(12):2137-47. doi: 10.1111/jth.12431.
Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis.
Sanglas L, Valnickova Z, Arolas JL, Pallarés I, Guevara T, Solà M, Kristensen T, Enghild JJ, Aviles FX, Gomis-Rüth FX.
Mol Cell. 2008 Aug 22;31(4):598-606. doi: 10.1016/j.molcel.2008.05.031.
Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
Coleman JR, Moore EE, Kelher MR, Jones K, Cohen MJ, Banerjee A, Silliman CC.
J Trauma Acute Care Surg. 2023 Jun 1;94(6):857-862. doi: 10.1097/TA.0000000000003911. Epub 2023 Feb 13.
Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.
Garabon JJW, Boffa MB.
J Thromb Thrombolysis. 2023 Aug;56(2):283-290. doi: 10.1007/s11239-023-02837-3. Epub 2023 Jun 13.
